Pantop%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Reduction of risk of NSAID-associated gastric ulcers in patients taking chronic NSAID therapy. * Pathological hypersecretory conditions, including Zollinger-Ellison syndrome. ## Adult Dosing * **Erosive Esophagitis (Healing):** 40 mg orally or intravenously once daily for up to 8 weeks. * **Erosive Esophagitis (Maintenance):** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily. * **NSAID-Associated Gastric Ulcer Prevention:** 40 mg orally once daily. * **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg orally or intravenously twice daily. Doses can be titrated up to 240 mg intravenously daily or 120 mg orally twice daily. ## Pediatric Dosing * **Patients 5 to 11 years:** * **Erosive Esophagitis:** 20 mg orally once daily for up to 8 weeks. * **GERD Symptoms:** 15 mg/kg orally once daily, not to exceed 40 mg daily, for up to 8 weeks. * **Patients 12 to 17 years:** * **Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks. ## Dose Adjustments No dose adjustment is typically required for hepatic or renal impairment, though caution may be advised in severe hepatic impairment. ## Contraindications * Known hypersensitivity to pantoprazole or any component of its formulation. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, abdominal pain, dizziness, and flatulence. Long-term use may be associated with an increased risk of C. difficile infection, bone fractures, vitamin B12 deficiency, and hypomagnesemia. ## Key Drug Interactions * **Certain Antiretrovirals:** Pantoprazole can decrease the absorption of drugs like rilpivirine and atazanavir. Avoid concomitant use. * **Methotrexate:** PPIs may increase methotrexate levels. Consider withholding pantoprazole during methotrexate treatment, especially at high doses. * **CYP2C19 Substrates:** Pantoprazole may alter the metabolism of drugs metabolized by CYP2C19 (e.g., clopidogrel, fluconazole). ## Monitoring * Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, arrhythmias). * Assess for bone fracture risk in patients on long-term therapy. * Monitor for signs of C. difficile infection. ## Clinical Pearls * Administer oral pantoprazole 30 minutes before a meal. * IV pantoprazole is available for patients unable to take oral medications. * Consider the potential for vitamin B12 deficiency with prolonged PPI use. * The risk of hypomagnesemia increases with longer duration of therapy. *** **Disclaimer:** This information is intended for clinical pharmacists and healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making therapeutic decisions. Dosing can vary based on individual patient factors and local institutional protocols.